Loading
Peroxisome Proliferator-activated Receptors · Journal article
Pharmaceuticals · September 7, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing that obesity is fundamentally a redox-imbalance disorder and surveying diverse antioxidant and metabolic interventions that share putative mechanisms (Nrf2/AMPK activation, glutathione restoration, mitochondrial stabilization) based on preclinical evidence. The authors acknowledge that clinical translation remains uncertain and requires further work on dosing, delivery, and safety—indicating the evidence is mechanistic and exploratory rather than practice-defining.
Narrative review. Obesity as a metabolic disorder; review does not define a specific human study population or clinical cohort..
Obesity pathophysiology characterized by persistent redox imbalance and chronic low-grade inflammation via NF-kB and NADPH oxidase pathways. Interventions reviewed include vitamins (A, B, C, E, D), minerals (zinc, selenium), amino acids (NAC, L-carnitine, taurine), and approved drugs (metformin, exenatide, fenofibrate, orlistat). Diverse interventions converge on restoring redox balance through Nrf2/AMPK activation, glutathione increase, and mitochondrial stabilization.
Author statement that clinical translation 'requires further clarification' underscores that dosing, delivery, and long-term safety remain undefined. Translation into clinical practice requires further clarification of dosing, delivery methods, and long-term safety.
Clinicians should recognize this as a mechanistic hypothesis and survey of preclinical literature, not evidence for clinical practice change. Implementation of any antioxidant-based strategy for obesity management remains premature pending human trials with defined dosing, delivery, and safety endpoints.
A narrative review of preclinical evidence proposing a mechanistic theory (oxidative stress as pathophysiological core) and surveying diverse interventions without new primary data, clinical trials, or human outcome evidence.
As stated by the source record.
Clinicians should recognize this as a mechanistic hypothesis and survey of preclinical literature, not evidence for clinical practice change. Implementation of any antioxidant-based strategy for obesity management remains premature pending human trials with defined dosing, delivery, and safety endpoints.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Obesity is increasingly recognized as a complex metabolic disorder characterized by persistent redox imbalance, rather than merely excess body weight. Its pathophysiology extends beyond energy imbalance to encompass chronic redox disruption. Expansion of adipose tissue, particularly in visceral depots, exceeds mitochondrial capacity, impairs antioxidant defenses such as superoxide dismutase, catalase, and glutathione peroxidase, and perpetuates chronic low-grade inflammation via nuclear factor kappa B (NF-kB) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase pathways. This review synthesizes preclinical evidence for diverse interventions, including vitamins A, B, C, E, and D; minerals such as zinc and selenium; amino acids such as N-acetylcysteine (NAC), L-carnitine, and taurine; various antioxidant compounds; and approved drugs including metformin, exenatide, fenofibrate, and orlistat. Despite differing structures and mechanisms, these interventions converge on restoring redox balance by activating nuclear factor erythroid 2–related factor 2 (Nrf2)/AMP-activated protein kinase (AMPK), increasing glutathione, and stabilizing mitochondria. However, translation of these preclinical findings into clinical practice requires further clarification of dosing, delivery methods, and long-term safety.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.